Characteristic | No. of Patients (%) | 5-year LR (%) | HR (95%CI) | P | 5-year RR (%) | HR (95%CI) | P |
---|---|---|---|---|---|---|---|
Age | Â | Â | Â | 0.005 | Â | Â | <0.001 |
 >45 years | 4864 (68.8) | 2.2 | 1.000 |  | 3.5 | 1.000 |  |
  ≤ 45 years | 2209 (31.2) | 3.1 | 1.450 (1.118–1.879) |  | 6.4 | 1.863 (1.492–2.325) |  |
Location | Â | Â | Â | <0.001 | Â | Â | <0.001 |
 Other quadrants | 5211 (73.7) | 1.9 | 1.000 |  | 3.6 | 1.000 |  |
 Inner quadrant | 1686 (23.8) | 3.6 | 1.729 (1.303–2.293) |  | 6.0 | 1.663 (1.305–2.120) |  |
 Unknown | 176 (2.5) |  |  |  |  |  |  |
Pathologic type | Â | Â | Â | 0.210 | Â | Â | 0.058 |
 Others | 893 (12.6) | 1.7 | 1.000 |  | 2.9 | 1.000 |  |
 Ductal | 6150 (87.0) | 2.6 | 1.309 (0.858–1.996) |  | 4.6 | 1.445 (0.986–2.118) |  |
 Unknown | 30 (0.4) |  |  |  |  |  |  |
T stagea | Â | Â | Â | <0.001 | Â | Â | <0.001 |
 T1–2 | 6967 (98.5) | 2.2 | 1.000 |  | 4.0 | 1.000 |  |
 T3–4 | 106 (1.5) | 24.2 | 13.018 (8.813–19.231) |  | 31.0 | 8.961 (6.075–13.216) |  |
N stagea | Â | Â | Â | <0.001 | Â | Â | <0.001 |
 N0 | 4604 (65.1) | 1.6 | 1.000 |  | 2.5 | 1.000 |  |
 N1 | 2142 (30.3) | 2.9 | 1.940 (1.459–2.580) |  | 5.9 | 2.922 (2.271–3.761) |  |
 N2 | 173 (2.4) | 9.1 | 5.549 (3.381–9.108) |  | 12.2 | 6.124 (3.825–9.804) |  |
 N3 | 154 (2.2) | 17.6 | 14.513 (9.488–22.199) |  | 33.1 | 18.467 (12.827–26.587) |  |
No. of node dissected | Â | Â | Â | 0.035 | Â | Â | 0.007 |
  ≥ 10 | 6485 (91.7) | 2.4 | 1.000 |  | 4.3 | 1.000 |  |
 <10 | 588 (8.3) | 4.9 | 1.598 (1.029–2.481) |  | 7.2 | 1.652 (1.145–2.384) |  |
Tumor grade | Â | Â | Â | 0.001 | Â | Â | 0.001 |
 1 | 409 (5.8) | 0 | 1.000 |  | 1.7 | 1.000 |  |
 2 | 3678 (52.0) | 2.1 | 4.748 (1.171–19.244) |  | 3.7 | 2.403 (1.062–5.440) |  |
 3 | 1713 (24.2) | 3.2 | 7.004 (1.715–28.607) |  | 5.6 | 3.503 (1.534–8.001) |  |
 Unknown | 1273 (18.0) |  |  |  |  |  |  |
Lymphovascular invasion | Â | Â | Â | 0.252 | Â | Â | 0.062 |
 No | 6668 (94.3) | 2.4 | 1.000 |  | 4.2 | 1.000 |  |
 Yes | 354 (5.0) | 4.7 | 1.357 (0.803–2.291) |  | 6.9 | 1.507 (0.977–2.325) |  |
 Unknown | 51 (0.7) |  |  |  |  |  |  |
Hormone receptor status | Â | Â | Â | <0.001 | Â | Â | <0.001 |
 Positive | 5212 (73.7) | 1.9 | 1.000 |  | 3.3 | 1.000 |  |
 Negative | 1745 (24.7) | 4.4 | 1.906 (1.467–2.476) |  | 7.8 | 1.990 (1.585–2.498) |  |
 Unknown | 116 (1.6) |  |  |  |  |  |  |
HER2 status | Â | Â | Â | 0.196 | Â | Â | 0.001 |
 Negative | 4536(64.1) | 2.2 | 1.000 |  | 3.8 | 1.000 |  |
 Positive | 1400 (19.8) | 3.1 | 1.241 (0.894–1.722) |  | 6.5 | 1.564 (1.204–2.031) |  |
 Unknown | 1137 (16.1) |  |  |  |  |  |  |
Ki67 | Â | Â | Â | 0.553 | Â | Â | 0.082 |
  ≥ 14% | 724 (10.2) | 4.8 | 1.000 |  | 7.5 | 1.000 |  |
 <14% | 712 (10.1) | 6.1 | 1.143 (0.734–1.780) |  | 10.2 | 1.378 (0.958–1.981) |  |
 Unknown | 5637 (79.7) |  |  |  |  |  |  |
Molecular subtypes | Â | Â | Â | Â | Â | Â | Â |
 Luminal A | 2397 (33.9) | 1.3 | 1.000 | <0.001 | 2.5 | 1.000 | <0.001 |
 Luminal B-Her2 negative | 573 (8.1) | 2.6 | 2.132 (1.303–3.486) |  | 5.3 | 1.920 (1.264–2.917) |  |
 Luminal B-Her2 positive | 810 (11.5) | 3.0 | 1.689 (1.032–2.765) |  | 5.8 | 1.944 (1.329–2.842) |  |
 Her2-enriched | 583 (8.2) | 3.4 | 2.029 (1.231–3.343) |  | 7.5 | 2.322 (1.564–3.447) |  |
 Triple-negative | 967 (13.7) | 4.9 | 2.711 (1.842–3.991) |  | 7.3 | 2.279 (1.626–3.194) |  |
 Unknown | 1743 (24.6) |  |  |  |  |  |  |
Endocrine therapyb | Â | Â | Â | 0.075 | Â | Â | 0.782 |
 Yes | 4400 (84.4) | 1.4 | 1.000 |  | 2.9 | 1.000 |  |
 No | 569 (10.9) | 2.7 | 1.535 (0.954–2.470) |  | 2.7 | 0.931 (0.563–1.541) |  |
 Unknown | 243 (4.7) |  |  |  |  |  |  |
Chemotherapy | Â | Â | Â | <0.001 | Â | Â | <0.001 |
 No | 1662 (23.5) | 1.3 | 1.000 |  | 1.9 | 1.000 |  |
 Yes | 5373 (76.0) | 2.8 | 2.424 (1.561–3.765) |  | 5.2 | 2.979 (1.993–4.451) |  |
   Unknown | 38 (0.5) |  |  |  |  |  |  |
Anti-Her2 target therapyc | Â | Â | Â | 0.079 | Â | Â | 0.415 |
 Yes | 321 (22.9) | 1.0 | 1.000 |  | 6.1 | 1.000 |  |
 No | 1067 (76.2) | 3.6 | 2.437 (0.871–6.814) |  | 6.7 | 1.271 (0.713–2.264) |  |
 Unknown | 12 (0.9) |  |  |  |  |  |  |